Savings That Last for TRIBENZOR Patients

1 card with 2 benefits to help your TRIBENZOR patients work toward BP goal

1. Lower co-pays over time*

  • 30- and 90-day retail and mail-order prescriptions are covered
  • Patients may pay as little as $5 per month for a 90-day prescription for an olmesartan-based product
  • Easy activation—only takes a few minutes

2. Generic benefit

Void in Massachusetts and Michigan

  • The Savings That Last co-pay card will cover up to 3 generic add-on antihypertensives for patients who do not reach BP goal while on an olmesartan-based medication
  • Benefit up to $25 per generic prescription; maximum benefit $75/month

Over 700,000 patients enrolled to date with over $150 million in savings since 2009.1

Send your patients to SavingsThatLast.com to register for these helpful benefits.

Email Email Print Print Increase Text SizeDecrease Text SizeText Size

Request Samples

Sign up to receive samples, savings cards, and educational materials for your patients.

Log in Register

Help patients work toward
BP goal

Hypertension Care provides patients
with proven products and
valuable services.

Learn More


Proven efficacy with TRIBENZOR

Triple-therapy TRIBENZOR helps your appropriate patients work toward BP goal.

Explore the Data

*Savings That Last Card Offer: Eligibility Criteria and Terms & Conditions.
Eligibility Criteria: Resident of US or Puerto Rico with valid prescription for product listed on front of the Savings That Last card. Generic benefit void in Massachusetts and Michigan. Not valid if enrolled in state or federally funded prescription benefit program (eg, Medicare Part D/Medicaid) or if prohibited by law.

Terms & Conditions: For patients with commercial insurance, savings benefits for these products do not cover insurance deductibles and apply after the following out-of-pocket expenses are met: $25 per prescription for months 1 to 6; $20 per prescription for months 7 to 12; and $15 per prescription after month 12. One month = 30-day tablet supply and 3 months = 90-day tablet supply. Maximum benefit of $70 per 30-day prescription and $125 per 90-day prescription. Patients without insurance receive $25 off retail price. Maximum benefit for each generic is $25 per prescription. Offers not valid with any other program, discount or incentive. It is illegal for any person to sell, purchase, or trade or to counterfeit the Savings That Last card. The Savings That Last card will be inactivated 120 days after last use. If the patient’s pharmacy does not accept the Savings That Last card, they should visit www.patientrebateonline.com for instructions on how to obtain savings benefit or call 1-855-809-5826. This is not insurance. By using the Savings That Last card, patients certify they meet the Eligibility Criteria and Terms & Conditions.

Pharmacist & Patient Questions: Call 1-855-809-5826 (8 am–8 pm ET, M–F).

Pharmacist Conditions: By using this offer, you certify that the Eligibility Criteria are met. Submit transaction to McKesson Corp, using BIN #610524. If primary coverage exists, input offer information as secondary coverage and transmit using COB segment of NCPDP transaction. Applicable discounts will be displayed in the transaction response. Acceptance of this offer and your submission of claims for the Savings That Last program are subject to LoyaltyScript® program Terms and Conditions posted at www.mckesson.com/mprstnc.

Daiichi Sankyo, Inc., reserves the right to rescind, revoke, or amend this program, at any time, without notice.

INDICATIONS:

BENICAR, AZOR, and TRIBENZOR are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which these drugs principally belong. There are no controlled trials demonstrating risk reduction with BENICAR, AZOR, or TRIBENZOR.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.

BENICAR HCT is indicated for the treatment of hypertension. BENICAR HCT is not indicated for initial therapy.

BENICAR, BENICAR HCT, AZOR, and TRIBENZOR can be used alone or with other antihypertensive agents.

AZOR is indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.

Initial therapy with AZOR is not recommended in patients ≥75 years of age or in hepatically impaired patients.

TRIBENZOR is not indicated for the initial therapy of hypertension.

Important Safety Information

for BENICAR®, BENICAR HCT®, AZOR®, and TRIBENZOR®

WARNING: FETAL TOXICITY

  • When pregnancy is detected, discontinue BENICAR, BENICAR HCT, AZOR, or TRIBENZOR as soon as possible
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS AND PRECAUTIONS: Fetal Toxicity

CONTRAINDICATIONS

Do not co-administer aliskiren with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR in patients with diabetes.

BENICAR HCT and TRIBENZOR are contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

WARNINGS AND PRECAUTIONS

Morbidity in Infants: Children <1 year of age must not receive BENICAR for hypertension.

Fetal Toxicity: BENICAR, BENICAR HCT, AZOR, and TRIBENZOR are Pregnancy Category D.

Hypotension in Volume- or Salt-Depleted Patients: In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (eg, those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR.

Impaired Renal Function: Monitor for worsening renal function in patients with renal impairment while on BENICAR, BENICAR HCT, AZOR, or TRIBENZOR.

In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (eg, patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. Similar results may be anticipated in patients treated with BENICAR, BENICAR HCT, AZOR, and TRIBENZOR.

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported, and similar results may be expected with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR.

BENICAR HCT is not recommended in patients with severe renal impairment. Avoid use of TRIBENZOR in patients with severely impaired renal function (creatinine clearance ≤30 mL/min). If progressive renal impairment becomes evident, consider withholding or discontinuing TRIBENZOR.

Sprue-like Enteropathy: Severe, chronic diarrhea with substantial weight loss has been reported in patients taking olmesartan months to years after drug initiation. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, exclude other etiologies. Consider discontinuation of BENICAR, BENICAR HCT, AZOR, or TRIBENZOR in cases where no other etiology is identified.

Hepatic Impairment: Initial therapy with AZOR or TRIBENZOR is not recommended in hepatically impaired patients. In patients with severe hepatic impairment, exercise caution with AZOR and avoid use of TRIBENZOR. Thiazides (a component in BENICAR HCT and TRIBENZOR) should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Electrolyte and Metabolic Imbalances: Due to the hydrochlorothiazide (HCTZ) component in BENICAR HCT and TRIBENZOR, observe patients for clinical signs of metabolic, fluid, or electrolyte imbalance.

Hypersensitivity Reaction: Hypersensitivity reactions to HCTZ (a component in BENICAR HCT and TRIBENZOR) may occur in patients with or without a history of allergy or bronchial asthma.

Systemic Lupus Erythematosus: Thiazides (a component in BENICAR HCT and TRIBENZOR) have been reported to cause exacerbation or activation of systemic lupus erythematosus.

Acute Myopia and Secondary Angle-Closure Glaucoma: Thiazides can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Discontinue HCTZ (a component in BENICAR HCT and TRIBENZOR) as rapidly as possible in these patients.

Vasodilation: Although vasodilation attributable to amlodipine (a component in AZOR and TRIBENZOR) is gradual in onset, acute hypotension has rarely been reported after oral administration. Patients with severe aortic stenosis may be at particular risk.

Increased Angina and/or Myocardial Infarction: Patients taking AZOR or TRIBENZOR, particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dose increase.

Laboratory Tests: There was a greater decrease in hemoglobin and hematocrit with AZOR compared to either component alone. Other lab abnormalities may include increased blood creatinine levels and hyperkalemia (olmesartan medoxomil), hepatic enzyme elevations (amlodipine), and increased cholesterol and triglyceride levels (HCTZ).

DRUG INTERACTIONS

Non-Steroidal Anti-Inflammatory Agents: Concurrent administration of non-steroidal anti-inflammatory drugs (NSAIDs) may lead to increased risk of renal impairment (including possible acute renal failure) and loss of antihypertensive effect of BENICAR, BENICAR HCT, AZOR, and TRIBENZOR.

Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on BENICAR, BENICAR HCT, AZOR, or TRIBENZOR and other agents that affect the RAS.

Avoid use of aliskiren with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR in patients with renal impairment (GFR <60 mL/min).

Concurrent Use with Colesevelam Hydrochloride: Concurrent administration of colesevelam hydrochloride with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR reduces the systemic exposure and peak plasma concentration of olmesartan. Consider administering olmesartan at least 4 hours before the colesevelam hydrochloride dose.

Effect of Amlodipine on Simvastatin: Due to increased exposure to simvastatin, when co-administered with amlodipine (a component in AZOR and TRIBENZOR), do not exceed doses of greater than 20 mg daily of simvastatin.

Lithium: Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of olmesartan or thiazide diuretics. Monitor lithium levels in patients receiving BENICAR, BENICAR HCT, AZOR, or TRIBENZOR and lithium.

ADVERSE REACTIONS

BENICAR: The only adverse reaction that occurred in >1% of patients treated with BENICAR and more frequently than placebo was dizziness (3% vs 1%).

BENICAR HCT: Adverse reactions reported in >2% of patients taking BENICAR HCT and more frequently than placebo included nausea (3% vs 0%), hyperuricemia (4% vs 2%), dizziness (9% vs 2%), and upper respiratory tract infection (7% vs 0%).

AZOR: The most common adverse reaction (incidence ≥3%) in patients treated with AZOR was edema.

TRIBENZOR: The most frequently reported adverse reaction was dizziness (5.8% to 8.9%). The other most frequent adverse reactions occurring in ≥2% of patients treated with TRIBENZOR were peripheral edema (7.7%), headache (6.4%), fatigue (4.2%), nasopharyngitis (3.5%), muscle spasms (3.1%), nausea (3.0%), upper respiratory tract infection (2.8%), diarrhea (2.6%), urinary tract infection (2.4%), and joint swelling (2.1%).

USE IN SPECIFIC PATIENT POPULATIONS

Nursing Mothers: Avoid use while nursing; discontinue either nursing or the drug.

 

Please see Full Prescribing Information for BENICAR, BENICAR HCT, AZOR, and TRIBENZOR.

  1. Data on file. Daiichi Sankyo, Inc., Parsippany, NJ.
  2. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.Clin Ther. 2010;32:1252-1269.
  3. TRIBENZOR® (olmesartan medoxomil, amlodipine, hydrochlorothiazide) Prescribing Information.

Email This Page

After completing the fields below and clicking "Submit," your colleague will receive an email with a link to this page.

* Required information

* Your First Name

* Your Last Name

* Your Email Address

* Recipient's Email Address

You are leaving TRIBENZORhcp.com.

Please note: You are about to leave the TRIBENZORhcp.com website and go to the  website.

Continue
Cancel